Wockhardt Zaynich clears CDSCO hurdle for India (2026)

What Wockhardt announced and why it matters

Wockhardt Ltd said it has received approval from the Central Drugs Standard Control Organisation (CDSCO) for import and marketing of its indigenously discovered and developed antibiotic, Zaynich (Zidebactam/Cefepime) in India. The company disclosed the development in a regulatory filing. The clearance is important because it advances a new antibiotic option in a market where drug-resistant gram-negative infections remain a major clinical challenge. Zaynich is positioned by the company as a novel combination designed for hard-to-treat infections. The announcement also comes amid heightened focus on antimicrobial resistance (AMR) and the need for newer therapies.

Approved indication: complicated UTI in adults

According to Wockhardt, the CDSCO approval covers the treatment of adult patients aged 18 years and above. The approved use is for complicated urinary tract infections (cUTI), including pyelonephritis. It also includes cases with concurrent gram-negative bacteremia alongside cUTI, as stated by the company. The indication matters because cUTIs and pyelonephritis can lead to serious complications, especially when caused by resistant pathogens. The company’s filing framed the approval around these clinical use cases, rather than a broader label.

Clinical evidence cited: ENHANCE-1 Phase 3 study

Wockhardt said the regulator’s nod is supported by results from the pivotal ENHANCE-1 study. It described ENHANCE-1 as a multinational, randomised, double-blind Phase 3 clinical trial. The trial evaluated the efficacy and safety of Zaynich compared with meropenem in patients with cUTI, including pyelonephritis. Meropenem is widely used as a key antibiotic in severe infections, and the comparator choice signals the clinical context highlighted by the company. The filing did not provide detailed numerical endpoints, but it did specify the study design and comparator.

Another regulatory track: SEC recommendation and DCGI decision

Separately, Wockhardt’s most advanced antibacterial candidate, Zaynich, has received a favourable recommendation for marketing approval from the Subject Expert Committee (SEC) of CDSCO, as reported in multiple updates included in the provided text. This positive opinion was described as a step that paves the way for final approval by the Drugs Controller General of India (DCGI). The text also notes that such expert committee recommendations are typically a precursor to DCGI approval, though not binding. One update said the key next trigger is a final decision from India’s drug controller. These regulatory steps are often watched closely by investors because they signal how quickly a product may move toward commercial rollout.

Dataset referenced: Phase 1, Phase 2, Phase 3 and compassionate use

The SEC’s favourable recommendation was said to be supported by a broad clinical dossier. The dataset referenced includes nine Phase 1 studies. It also includes a multi-indication Phase 2 study in meropenem-resistant infections. In addition, it cites a global Phase 3 study in complicated urinary tract infections and acute pyelonephritis (cUTI/AP). The dossier also referenced data from 85 compassionate-use cases. The materials described this as a comprehensive review of the product’s non-clinical and clinical package.

How Zaynich works: cefepime plus zidebactam

Zaynich is described as a combination of two agents, cefepime and zidebactam. Cefepime is referenced as a fourth-generation cephalosporin antibiotic in the provided text. The product is described as disrupting cell wall formation and binding a key bacterial protein (PBP2) essential for survival. Another description in the text refers to zidebactam as a novel β-lactam enhancer. Together, these descriptions explain why the company positions Zaynich for drug-resistant gram-negative infections.

Standards and resistance focus: CLSI breakpoint and XDR coverage

Wockhardt also pointed to recognition by the Clinical and Laboratory Standards Institute (CLSI). The company said CLSI has assigned Cefepime/Zidebactam an investigational susceptible breakpoint of 64 mg/L. It said this supports the potential to cover clinically important extensively drug-resistant (XDR) gram-negative pathogens in critically ill patients. The reference to investigational breakpoints is relevant because laboratories and clinicians often rely on such benchmarks to interpret susceptibility data. The text frames this as supportive evidence for broad-spectrum potential.

Real-world evidence cited: efficacy claim in meropenem-resistant infections

The provided text also includes a real-world study claim. It states that Zaynich has demonstrated over 97 per cent clinical efficacy in a real-world study of meropenem-resistant infections. The study was said to be conducted across 15 leading tertiary care hospitals in India. The text does not provide details such as patient counts, endpoints, or follow-up duration, but it does highlight the setting and the resistance context. This is the same resistance backdrop where newer combinations are typically evaluated for clinical utility.

Key facts at a glance

Market impact: what investors will track next

For investors, the immediate focus is on regulatory sequencing and label clarity. The materials provided include both a CDSCO approval for import and marketing for a specific adult cUTI indication and an SEC recommendation that typically precedes a final DCGI decision. Any subsequent DCGI communication will likely be treated as the next confirmation point, given that expert panel recommendations are described as non-binding. Another update in the provided text also says approval is awaited in India, the US, and the EU for a Zaynich launch, indicating the product is being tracked across jurisdictions. In India, one note in the text adds that a commercial rollout could begin soon post-DCGI nod, with prioritisation of ICUs.

Why the development is being watched in AMR

The story stands out because the text frames Zaynich as an indigenously developed antibiotic and ties it to AMR needs, particularly against XDR gram-negative pathogens. The combination approach, along with Phase 3 evidence versus meropenem and the CLSI investigational breakpoint reference, underlines its positioning for serious hospital infections. The inclusion of compassionate-use data and real-world hospital experience indicates the company has also leaned on multiple evidence types while approaching regulators. For the Indian pharma sector, regulatory progress on a novel antibacterial candidate is also notable because antibiotics often face high development costs and complex stewardship-led adoption.

Conclusion

Wockhardt’s filings and the reported expert committee outcome together show Zaynich moving through key regulatory milestones in India. The company has tied its case to Phase 3 ENHANCE-1 data, a broader clinical dossier, and additional references such as CLSI’s investigational breakpoint. The next watchpoint, as stated in the provided text, is the final decision by the DCGI following the SEC recommendation, alongside any further clarity on rollout plans and additional markets.